{
  "trial_id": "NCT01084538",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Subject is more than 18 years of age and diagnosed with secondary hyperparathyroidism",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "has a pretreatment iPTH > 300 pg/mL, receiving chronic hemodialysis.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Treatment with Zemplar Injection is indicated clinically according to the criteria of participating investigator.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Subject has a corrected serum calcium >10.5 mg/dL, serum phosphorus > 6.5 mg/dL or subjects with corrected Ca x P>65.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Subject has known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients, or has participated in clinical study within the last month",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient is a 22yo F with systemic mastocytosis, presenting with flushing and tachycardia. She responded well to IV steroids and diphenydramine.",
  "_meta": {
    "topic_id": "10",
    "trial_id": "NCT01084538",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}